MARKET

NTEC

NTEC

Intec Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5336
+0.0275
+5.43%
Opening 09:55 11/21 EST
OPEN
0.5400
PREV CLOSE
0.5061
HIGH
0.5500
LOW
0.5000
VOLUME
43.20K
TURNOVER
--
52 WEEK HIGH
9.25
52 WEEK LOW
0.4100
MARKET CAP
13.91M
P/E (TTM)
-1.2967
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NTEC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NTEC News

  • Intec Pharma to Participate in Jefferies London Healthcare Conference
  • PR Newswire.11/13 12:00
  • Intec Pharma Q3 EPS $(0.61) Down From $(0.28) YoY
  • Benzinga.11/12 12:16
  • Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update
  • PR Newswire.11/12 12:00
  • Top Marijuana Stocks on the NASDAQ
  • Investopedia.10/26 23:01

More

Industry

Biotechnology & Medical Research
-0.08%
Pharmaceuticals & Medical Research
-0.09%

Hot Stocks

Name
Price
%Change

About NTEC

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
More

Webull offers Intec Pharma Ltd (NTEC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.